Gilead's Kite doubles down on Arcellx's blood cancer cell therapies with $285M
Gilead’s cell therapy unit Kite wants more of what it initially got from Arcellx last December, buying $200 million worth of equity in Arcellx and doling out $85 million in cash to expand their partnership.
The deal arrives three months after the FDA lifted a partial clinical hold on the duo’s partnered CART-ddBCMA candidate in multiple myeloma. The re-upped pact will now expand that scope to include lymphomas, the biotechs said Wednesday morning, giving investors a little bit more lead time ahead of the annual American Society of Hematology conference than they did with last year’s initial announcement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
